Home — Centre for Medicines Discovery (CMD)

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

News

This figure illustrates the multiscale platform used for the discovery and validation of PAK1 kinase activators. The approach begins with PAK1-activating peptide as a guide to identify potential binding sites for virtual screening of small-molecule activators. Hits are then validated using mass spectrometry-based assays to confirm PAK1 activation, and further characterised through biophysical and structural studies to elucidate the mechanism of action. Finally, the therapeutic potential of the PAK1 activators is evaluated in both in vitro and in vivo models of cardiac hypertrophy.

Oxford-led study reveals new way to activate protein kinases, opening new therapeutic possibilities

16 April 2026

Diagram showing how genetic instability in normal cells leads to tumour formation through acquired mutations. It illustrates two outcomes: mutations activating cancer-driving pathways, and cancer cells becoming dependent on specific signalling pathways, both of which can be targeted by precision medicines.

Oxford University spinout Dark Blue Therapeutics acquired to advance leukaemia treatment

31 March 2026

Schematic showing how the CBH-002 probe detects different types of PRMT5 inhibitors and senses changes in cellular metabolic state of SAM. Credit: Rothweiler et al., Nat Comm 2025

Oxford researchers develop first live-cell assay linking cancer tumour metabolism to drug effectiveness

9 December 2025

Discovery reveals 'handbrake' that controls cancer drug response

10 November 2025

More news

Publications

iNOS modulates inflammatory responses in an NO-independent manner through direct interaction with IRG1 in mitochondria.

Diotallevi M. et al, (2026), Nat Metab

Ugi-Tetrazole-Derived α‑Aminomethyl Scaffolds Reveal Unexpected Binding Modes in SARS-CoV‑2 3CLpro.

van der Straat R. et al, (2026), ACS Med Chem Lett, 17, 856 - 865

Proteomic Snapshots of Structural Cross-Linking Rearrangements in Ca2+/Calmodulin-Dependent Kinase-1-Delta Associated with Its Regulation by ATP, Ca2+/Calmodulin, and Reduction Potential.

Mbabala L. et al, (2026), J Proteome Res, 25, 1914 - 1928